Journal rankings · indicator year 2010
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2010
Biochemistry, Genetics and Molecular Biology journal rankings 2010
1,003 ranked journals · Field in Life Sciences
Biochemistry, Genetics and Molecular Biology has 1,003 ranked journals in 2010. The median journal has an OJR of 0.98, below the world average of 1.00, up 0.04 on 2009; Q1 starts at OJR 1.55. The top three are Nature Genetics, Cell, and Pharmacological Reviews.
Ranks and citation indicators: 2010. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2007–2009, the window the 2010 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Biochemistry, Genetics and Molecular Biology (14)
Up to Life Sciences1,003 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2009. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2007–2009, the window the 2010 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2007–2009 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2001 to 2010. | Compare |
|---|---|---|---|---|---|---|---|
1Nature GeneticsNature Portfolio · United States | 11.32Q1 | 31.40 4.60 up from 2009 | 920 | 58% | $12,690 | ||
2CellCell Press · United States | 9.11Q1 | 23.30 1.04 up from 2009 | 1,786 | 99% | $11,400 | ||
3Pharmacological ReviewsAmerican Society for Pharmacology and Experimental Therapeutics · United States | 8.92Q1 | 22.35 3.32 up from 2009 | 54 | 55% | $4,500 | ||
4NatureNature Portfolio · United Kingdom | 6.79Q1 | 11.40 0.41 up from 2009 | 9,876 | 27% | $12,690 | ||
5Cell stem cellElsevier BV · United States | 6.25Q1 | 17.06 2.20 up from 2009 | 475 | 100% | $10,400 | ||
6Biotechnology AdvancesElsevier BV · United Kingdom | 6.10Q1 | 9.59 0.78 down from 2009 | 214 | 14% | $5,460 | ||
7FEMS Microbiology ReviewsOAOxford University Press · Netherlands | 5.82Q1 | 13.07 2.01 up from 2009 | 154 | 66% | $3,297 | ||
8Journal of Clinical InvestigationOAAmerican Society for Clinical Investigation · United States | 5.59Q1 | 13.19 0.43 down from 2009 | 1,397 | 100% | $5,200 | ||
9Nature Cell BiologyNature Portfolio · United Kingdom | 5.49Q1 | 14.10 0.02 up from 2009 | 731 | 50% | $12,690 | ||
10Cell MetabolismCell Press · United States | 5.44Q1 | 14.75 0.65 up from 2009 | 401 | 100% | $10,400 | ||
11ScienceAmerican Association for the Advancement of Science · United States | 5.26Q1 | 7.40 0.47 up from 2009 | 13,564 | 23% | — | ||
12Nature BiotechnologyNature Portfolio · United States | 5.24Q1 | 10.30 0.20 down from 2009 | 1,087 | 28% | $12,690 | ||
13Systematic BiologyOxford University Press · United States | 4.97Q1 | 9.11 0.89 down from 2009 | 261 | 42% | $2,166 | ||
14Molecular CellElsevier BV · United States | 4.91Q1 | 13.39 0.95 down from 2009 | 1,097 | 100% | $10,400 | ||
15Proceedings of the National Academy of SciencesNational Academy of Sciences · United States | 4.79Q1 | 11.03 0.23 up from 2009 | 11,802 | 99% | — | ||
16The American Journal of Human GeneticsElsevier BV · United States | 4.77Q1 | 11.29 0.32 down from 2009 | 737 | 95% | $5,150 | ||
17Progress in Lipid ResearchElsevier BV · United Kingdom | 4.75Q1 | 10.69 1.09 up from 2009 | 74 | 36% | $5,530 | ||
18PLoS BiologyOAPublic Library of Science · United States | 4.74Q1 | 10.36 0.67 down from 2009 | 893 | 100% | $5,500 | ||
19Molecular Biology and EvolutionOAOxford University Press · United States | 4.58Q1 | 5.99 5.70 down from 2009 | 879 | 78% | $3,418 | ||
20Molecular Aspects of MedicineElsevier BV · United Kingdom | 4.55Q1 | 14.55 6.44 up from 2009 | 110 | 37% | $5,220 | ||
21Drug Resistance UpdatesElsevier BV · United Kingdom | 4.49Q1 | 11.12 0.43 down from 2009 | 62 | 20% | $5,410 | ||
22Molecular Systems BiologyOASpringer Nature · United Kingdom | 4.42Q1 | 10.66 1.94 down from 2009 | 261 | 100% | $7,990 | ||
23Pharmacology & TherapeuticsElsevier BV · United States | 4.40Q1 | 9.28 0.60 down from 2009 | 298 | 28% | $5,660 | ||
24PLoS GeneticsOAPublic Library of Science · United States | 4.34Q1 | 10.87 0.16 down from 2009 | 1,062 | 100% | $3,043 | ||
25Cell Host & MicrobeCell Press · United States | 4.18Q1 | 10.77 1.46 up from 2009 | 377 | 100% | $10,400 | ||
26Orphanet Journal of Rare DiseasesOABioMed Central · United Kingdom | 4.09Q1 | 8.03 0.26 up from 2009 | 112 | 100% | $2,990 | ||
27Briefings in BioinformaticsOAOxford University Press · United Kingdom | 4.00Q1 | 12.12 4.14 up from 2009 | 160 | 79% | $3,885 | ||
28Nature ProtocolsNature Portfolio · United States | 3.99Q1 | 10.82 2.79 up from 2009 | 737 | 37% | — | ||
29Biochimica et Biophysica Acta (BBA) - Reviews on CancerElsevier BV · Netherlands | 3.96Q1 | 10.29 0.62 up from 2009 | 106 | 23% | $5,070 | ||
30Nuclear Receptor SignalingSAGE Publishing · United States | 3.95Q1 | 12.32 3.32 up from 2009 | 35 | 100% | — | ||
31Mutation Research/Reviews in Mutation ResearchElsevier BV · Netherlands | 3.88Q1 | 10.21 2.26 up from 2009 | 101 | 20% | $4,160 | ||
32TrAC Trends in Analytical ChemistryElsevier BV · Netherlands | 3.86Q1 | 5.88 0.69 up from 2009 | 379 | 15% | $5,150 | ||
33Nature Structural & Molecular BiologyNature Portfolio · United States | 3.85Q1 | 11.21 1.49 up from 2009 | 718 | 68% | $12,690 | ||
34Developmental CellElsevier BV · United States | 3.82Q1 | 11.15 0.59 up from 2009 | 633 | 100% | $10,400 | ||
35The EMBO JournalOASpringer Nature · Germany | 3.77Q1 | 10.54 0.24 up from 2009 | 1,143 | 93% | $7,990 | ||
36Nature MethodsNature Portfolio · United States | 3.76Q1 | 9.78 0.48 up from 2009 | 916 | 35% | $12,690 | ||
37Critical Reviews in MicrobiologyTaylor & Francis · United States | 3.73Q1 | 7.37 2.63 up from 2009 | 46 | 0% | — | ||
38Medicinal Research ReviewsWiley · United States | 3.63Q1 | 7.54 0.96 down from 2009 | 92 | 18% | $4,980 | ||
39Nature Chemical BiologyNature Portfolio · United States | 3.62Q1 | 9.14 1.58 up from 2009 | 607 | 43% | $12,690 | ||
40Molecular & Cellular ProteomicsOAElsevier BV · United States | 3.58Q1 | 8.29 0.35 down from 2009 | 652 | 99% | $3,430 | ||
41Circulation ResearchLippincott Williams & Wilkins · United States | 3.51Q1 | 8.89 0.18 up from 2009 | 1,098 | 73% | — | ||
42EMBO Molecular MedicineOASpringer Nature · United Kingdom | 3.42Q1 | 6.44no 2009 value | 59 | 100% | $7,990 | — | |
43Human Molecular GeneticsOxford University Press · United Kingdom | 3.40Q1 | 8.31 0.38 up from 2009 | 1,335 | 77% | $4,390 | ||
44Stem CellsOxford University Press · United States | 3.37Q1 | 8.38 0.38 down from 2009 | 1,055 | 62% | $4,477 | ||
45Expert Reviews in Molecular MedicineOACambridge University Press · United Kingdom | 3.33Q1 | 8.55 1.77 up from 2009 | 110 | 35% | $3,550 | ||
46Evolutionary ApplicationsOAWiley · United Kingdom | 3.32Q1 | 6.32 0.99 up from 2009 | 97 | 100% | $4,320 | ||
47Molecular EcologyWiley · United Kingdom | 3.30Q1 | 6.48 0.02 up from 2009 | 1,252 | 31% | $5,150 | ||
48Drug Discovery TodayElsevier BV · Netherlands | 3.26Q1 | 6.52 0.51 up from 2009 | 459 | 8% | $4,720 | ||
49Cancer ResearchAmerican Association for Cancer Research · United States | 3.24Q1 | 9.16 0.66 up from 2009 | 4,004 | 10% | — | ||
50Journal of NanobiotechnologyOABioMed Central · United Kingdom | 3.17Q1 | 5.46 1.50 down from 2009 | 35 | 100% | $3,790 |
Subfields of Biochemistry, Genetics and Molecular Biology, compared.
- Molecular Biology844
- Genetics95
- Cancer Research21
- Cell Biology20
- Molecular Medicine7
- Biophysics6
- Biochemistry3
- Clinical Biochemistry2
- Structural Biology2
- Developmental Biology1
- Endocrinology1
- Physiology1
- Aging0
- Biotechnology0
Journals
Citations made in 2010. Corpus-wide, 73.2% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
297 additional Biochemistry, Genetics and Molecular Biology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2007–2009, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2010. Publication window: 2007–2009. How these summaries are calculated
- Ranked journals
- 1,003
- Window papers (baseline)
- 565,943 +19.9% from indicator year 2007
- Median OJR
- 0.98 +10.1% from indicator year 2007
- Rising journals (2025)
- 141Comparison-group list (141)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2007–2009 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 609 | 650 | 696 | 742 | 765 | 806 | 835 | 888 | 919 | 951 | 1,003 | 1,064 | 1,125 | 1,172 | 1,217 | 1,271 | 1,311 | 1,339 | 1,365 | 1,369 | 1,349 | 1,339 | 1,358 | 1,366 | 1,355 | 1,367 | |
| Window papers (baseline) | 310,927 | 335,262 | 354,210 | 375,343 | 388,415 | 415,247 | 441,606 | 472,036 | 497,712 | 532,780 | 565,943 | 595,190 | 615,359 | 631,115 | 652,778 | 672,042 | 683,714 | 684,441 | 678,826 | 679,352 | 690,127 | 717,801 | 750,552 | 768,440 | 764,327 | 768,613 | |
| Median OJR | 0.628 | 0.634 | 0.68 | 0.76 | 0.81 | 0.8465 | 0.872 | 0.894 | 0.921 | 0.95 | 0.98 | 1.03 | 1.02 | 0.990 | 0.986 | 0.97 | 0.96 | 0.93 | 0.925 | 0.915 | 0.912 | 0.90 | 0.890 | 0.8474 | 0.853 | 0.871 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 1.9% | 1,206 journals |
| Retracted papers per 1,000 | Pooled rate: 4.798 per 1,000 | 1,059 journals |
| Output growth | Median: -6.4% | 1,233 journals |
| Open access share | Median: 100.0% | 1,367 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,300 | 943 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 24.4% | 1,335 journals |
| Review share | Median: 0.3% | 1,367 journals |
| Articles-only OJR | Median: 0.87 | 1,336 journals |
| Uncited share | Median: 22.7% | 1,367 journals |
| Citation concentration | Median: 42.1% | 1,363 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.